99 related articles for article (PubMed ID: 15897911)
21. Non-sufficient cell cycle control as possible clue for the resistance of human malignant glioma cells to clinically relevant treatment conditions.
Trog D; Moenkemann H; Breipohl W; Schueller H; Schild H; Golubnitschaja O
Amino Acids; 2007; 32(3):373-9. PubMed ID: 17077962
[TBL] [Abstract][Full Text] [Related]
22. Melanoma patients respond to a new HLA-A*01-presented antigenic ligand derived from a multi-epitope region of melanoma antigen TRP-2.
Paschen A; Jing W; Drexler I; Klemm M; Song M; Müller-Berghaus J; Nguyen XD; Osen W; Stevanovic S; Sutter G; Schadendorf D
Int J Cancer; 2005 Oct; 116(6):944-8. PubMed ID: 15856458
[TBL] [Abstract][Full Text] [Related]
23. Induction of human glioma-specific cytotoxic T-lymphocyte lines by autologous tumor stimulation and interleukin 2.
Miyatake S; Handa H; Yamashita J; Yamasaki T; Ueda M; Namba Y; Hanaoka M
J Neurooncol; 1986; 4(1):55-64. PubMed ID: 3489081
[TBL] [Abstract][Full Text] [Related]
24. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
25. A novel recombinant protein of IP10-EGFRvIIIscFv and CD8(+) cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice.
Wang X; Lu XL; Zhao HY; Zhang FC; Jiang XB
Cancer Immunol Immunother; 2013 Jul; 62(7):1261-72. PubMed ID: 23640602
[TBL] [Abstract][Full Text] [Related]
26. An altered peptide ligand for naïve cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity.
Tang Y; Lin Z; Ni B; Wei J; Han J; Wang H; Wu Y
Cancer Immunol Immunother; 2007 Mar; 56(3):319-29. PubMed ID: 16906394
[TBL] [Abstract][Full Text] [Related]
27. HLA Tetramer Based Artificial Antigen-Presenting Cells Efficiently Stimulate CTLs Specific for Malignant Glioma.
Jiang X; Lu X; Liu R; Zhang F; Zhao H
Clin Cancer Res; 2007 Dec; 13(24):7329-34. PubMed ID: 18094414
[TBL] [Abstract][Full Text] [Related]
28. [CTL precursor-oriented peptide vaccine therapy for malignant glioma].
Yajima N; Yamanaka R; Tanaka R; Shigemori M; Mine T; Itoh K
Nihon Rinsho; 2005 Sep; 63 Suppl 9():582-7. PubMed ID: 16201585
[No Abstract] [Full Text] [Related]
29. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy and immunotherapy of brain tumors: what the epileptologist must know.
Rogers LR
Epilepsia; 2013 Dec; 54 Suppl 9():105-8. PubMed ID: 24328882
[TBL] [Abstract][Full Text] [Related]
31. Peptide vaccine.
Izumoto S
Adv Exp Med Biol; 2012; 746():166-77. PubMed ID: 22639167
[TBL] [Abstract][Full Text] [Related]
32. Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.
Yamini B; Yu X; Pytel P; Galanopoulos N; Rawlani V; Veerapong J; Bickenbach K; Weichselbaum RR
Clin Cancer Res; 2007 Oct; 13(20):6217-23. PubMed ID: 17947489
[TBL] [Abstract][Full Text] [Related]
33. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
[TBL] [Abstract][Full Text] [Related]
34. Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells.
Glazyrin AL; Kan-Mitchell J; Mitchell ML
Cancer Immunol Immunother; 2003 Mar; 52(3):171-8. PubMed ID: 12649746
[TBL] [Abstract][Full Text] [Related]
35. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Jordan JT; Sun W; Hussain SF; DeAngulo G; Prabhu SS; Heimberger AB
Cancer Immunol Immunother; 2008 Jan; 57(1):123-31. PubMed ID: 17522861
[TBL] [Abstract][Full Text] [Related]
36. Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization.
Gomez GG; Varella-Garcia M; Kruse CA
Cancer Genet Cytogenet; 2006 Mar; 165(2):121-34. PubMed ID: 16527606
[TBL] [Abstract][Full Text] [Related]
37. Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma.
Ueda R; Low KL; Zhu X; Fujita M; Sasaki K; Whiteside TL; Butterfield LH; Okada H
J Transl Med; 2007 Dec; 5():68. PubMed ID: 18093336
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of malignant gliomas.
Maleci A
J Neurosurg Sci; 1989; 33(1):77-82. PubMed ID: 2674361
[TBL] [Abstract][Full Text] [Related]
39. Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes.
Merchant RE; Baldwin NG; Rice CD; Bear HD
Neurol Res; 1997 Apr; 19(2):145-52. PubMed ID: 9175143
[TBL] [Abstract][Full Text] [Related]
40. Immunomonitoring in glioma immunotherapy: current status and future perspectives.
Lamano JB; Ampie L; Choy W; Kesavabhotla K; DiDomenico JD; Oyon DE; Parsa AT; Bloch O
J Neurooncol; 2016 Mar; 127(1):1-13. PubMed ID: 26638171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
